Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial.

File Description SizeFormat 
leaderfinalpolyvascular.docxFile embargoed until 15 November 2018367.7 kBMicrosoft Word    Request a copy
Title: Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial.
Author(s): Verma, S
Bhatt, DL
Bain, SC
Buse, JB
Mann, JFE
Marso, SP
Nauck, MA
Poulter, NR
Pratley, RE
Zinman, B
Michelsen, MM
Monk Fries, T
Rasmussen, S
Leiter, LA
LEADER Publication Committee on behalf of the LEADER Trial Investigators
Item Type: Journal Article
Publication Date: 15-May-2018
Date of Acceptance: 1-May-2018
URI: http://hdl.handle.net/10044/1/61511
DOI: https://dx.doi.org/10.1161/CIRCULATIONAHA.118.033898
ISSN: 0009-7322
Publisher: American Heart Association
Start Page: 2179
End Page: 2183
Journal / Book Title: Circulation
Volume: 137
Issue: 20
Copyright Statement: © 2018 American Heart Association, Inc.
Keywords: atherosclerosis
diabetes mellitus, type 2
glucagon-like peptide 1
liraglutide
myocardial infarction
LEADER Publication Committee on behalf of the LEADER Trial Investigators
atherosclerosis
diabetes mellitus, type 2
glucagon-like peptide 1
liraglutide
myocardial infarction
1103 Clinical Sciences
1102 Cardiovascular Medicine And Haematology
1117 Public Health And Health Services
Cardiovascular System & Hematology
Publication Status: Published
Conference Place: United States
Embargo Date: 2018-11-15
Online Publication Date: 2018-05-15
Appears in Collections:National Heart and Lung Institute
Faculty of Medicine



Items in Spiral are protected by copyright, with all rights reserved, unless otherwise indicated.

Creative Commons